Ignite Creation Date:
2024-05-06 @ 3:36 PM
Last Modification Date:
2024-10-26 @ 1:52 PM
Study NCT ID:
NCT04685590
Status:
RECRUITING
Last Update Posted:
2023-12-14
First Post:
2020-12-22
Brief Title:
Senolytic Therapy to Modulate the Progression of Alzheimers Disease SToMP-AD Study
Sponsor:
Wake Forest University Health Sciences
Organization:
Wake Forest University Health Sciences
Study Overview
Official Title:
Phase II Clinical Trial to Evaluate the Safety and Feasibility of Senolytic Therapy in Alzheimers Disease
Status:
RECRUITING
Status Verified Date:
2023-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
SToMP-AD
Brief Summary:
The objective of the study is to determine the safety feasibility and efficacy of senolytics in older adults with amnestic mild cognitive impairment MCI or early-stage AD Clinical Dementia Rating CDR05 or 1 who are tau PET positive
Detailed Description:
This study is a Phase II multi-site randomized double-blind placebo controlled trial to determine safety feasibility and efficacy of senolytics in older adults with amnestic mild cognitive impairment MCI or early-stage AD Clinical Dementia Rating CDR05 or 1 who are tau PET positive
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None